Making a difference
17 November 2014
Anna is making a difference every day to the lives of her patients. With your support, you can make a difference too.
When Melanoma Institute Australia (MIA) patients at the Poche Centre are first diagnosed with advanced melanoma Anna Hoadley is there.
She is our Clinical Nurse Consultant, and serves as a link between patients and their doctor. Anna is someone they can call with questions and to help co-ordinate their care during what is often the most emotionally tumultuous and stressful time of their lives.
When not in the clinic Anna is on the phone to patients talking about treatment options, dealing with side-effects, co-ordinating tests and scans, speaking to family members, organising referrals, triaging new patient referrals, and much more!
“Having someone to co-ordinate care and understand medically what is going on, to understand their treatments and help improve their quality of life, is so important to our patients,” says Anna.
“Without a Clinical Nurse Consultant, there would be a lot more emotional and physical struggle for our patients.”
One of the hundreds of patients that Anna looks after each year is Trish Nugent. Trish has stage 4 melanoma and has benefitted greatly from Anna’s care.
“Knowing that somebody is helping in such a significant way, to keep me around so that I can be with my family for longer, makes me so very grateful,” Trish says.
“Anna is my inspiration and a joy to see every three weeks, even in the low times. She keeps me fighting.”
With more funding we can expand this program to fund Clinical Nurse Consultants at our other affiliate locations and ensure every patient receives this same exceptional level of care
Your donation today will make a tangible difference to the lives of people, like Trish, and make their struggle that much easier by providing a helping hand in their time of need.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.